Trending Clinical Topics for June 2019

Ryan Syrek


June 28, 2019

Trending Clinical Topic of the Week (June 8-14): Headache

New treatment options for two different types of headache and an overview of important information about a third type helped make this common condition the top trending clinical topic of the week. The US Food and Drug Administration (FDA) recently approved galcanezumab-gnlm (Emgality), a calcitonin gene-related peptide antagonist, for the treatment of episodic cluster headache in adults. It is the first FDA-approved medication intended to reduce the frequency of episodic cluster headache attacks. In a clinical trial, patients taking galcanezumab experienced 3.5 fewer weekly cluster headache attacks than patients receiving placebo during the 3-week study.

The FDA also recently cleared a noninvasive neuromodulation device for use in patients experiencing acute migraine pain. Nerivio Migra (Theranica) is worn on the upper arm and uses smartphone-controlled electronic pulses for conditioned pain modulation. It is indicated for use in adults who do not have chronic migraine (> 15 days per month). In a prospective, randomized, double-blind, placebo-controlled study involving 252 patients, the device demonstrated significant efficacy in relieving pain related to single and multiple attacks.

A recent editorial collaboration between Medscape and the American Headache Society explored a third type of headache. Thunderclap headaches have an abrupt onset and reach maximum intensity within 1 minute and last for at least 5 minutes. The collaboration explored various diagnostic approaches and treatment options for secondary causes of these headaches, which include subarachnoid hemorrhage, found to be the source in 10%-25% of patients. Because headaches are so common, any new information is enthusiastically received. Thus, it's no surprise that headache is this week's top trending clinical topic.

Stay current on all headache-related information.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.